- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Pathologist onsite cuts repeat thyroid biopsies
Having a pathologist onsite during ultrasound-guided thyroid biopsies can decrease the number of repeat biopsies performed due to an inadequate sample, according to a study presented at the American Roentgen Ray Society annual meeting.
Having a pathologist onsite during ultrasound-guided thyroid biopsies can decrease the number of repeat biopsies performed due to an inadequate sample, according to a study presented at the American Roentgen Ray Society annual meeting.
University of North Carolina researchers compared 200 biopsies performed with a pathologist onsite and 200 with no pathologist present. All other factors being equal, 13.5% of biopsies performed without a pathologist onsite needed to be repeated, compared with only 5% where a pathologist was onsite, according to the research.
An inadequate sample is one where the pathologist deems there is an insufficient amount of tissue to make a diagnosis.
“We recommend that radiologists performing large numbers of thyroid biopsies use onsite pathology as it may reduce the need for repeat biopsy by up to 60%,” said Dr. Wui K. Chong, lead author of the study and an associate professor of radiology at UNC.
Can Deep Learning Radiomics with bpMRI Bolster Accuracy for Prostate Cancer Prognosis?
January 22nd 2025An emerging deep learning radiomics model based on biparametric MRI (bpMRI) offered a 14 to 17 percent higher AUC range than PI-RADS scoring for predicting the aggressiveness of prostate cancer, according to new research findings.
PET Agent Gets FDA Fast Track Designation for Cardiac AL and ATTR Amyloidosis
January 22nd 2025Previously approved for the detection of neuritic beta amyloid plaque, the PET agent (18F)florbetaben is currently being evaluated in a phase 3 multicenter trial for the diagnosis of cardiac amyloidosis.
Seven Takeaways from New CT and MRI Guidelines for Ovarian Cancer Staging
January 20th 2025In an update of previous guidelines from the European Society of Urogenital Radiology published in 2010, a 21-expert panel offered consensus recommendations on the utility of CT, MRI and PET-CT in the staging and follow-up imaging for patients with ovarian cancer.
